- Published at
- by rttnews.com
mixed
mixed
Biotech Stocks Facing FDA Decision In September 2024
As September unfolds, let us review some of the regulatory news that made headlines last month and look ahead to what this month has in store..
News for Orphazyme A/S (OZYMF)
- Published at
- by medium.com
mixedmixedIdiopathic Inflammatory Myopathy Treatment Market Expansion Fueled by Advancements in Autoimmune Disease Treatments
As per Fortune Business Insights’ report, the idiopathic inflammatory myopathy treatment Market share sector attained a worth of USD 652.3 million in 2018. Forecasts indicate a promising path ahead…- Published at
- by marketwatch.com
positivepositiveGalecto Inc. Stock Quote (U.S.: Nasdaq)
GLTO | Complete Galecto Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.- Published at
- by marketscreener.com
positivepositiveChange in management
The board of directors and CEO/CFO Anders Fink Vadsholt has today entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CEO/CFO of the Company. Regardless, Mr. Vadsholt... | May 30, 2023- Published at
- by marketscreener.com
neutralneutralMajor shareholder announcement
Company announcement Orphazyme A/SNo. 09/2023 Ole Maal?Vej 3DK-2200 Copenhagen N ... | May 17, 2023- Published at
- by globenewswire.com
mixedmixedAmyotrophic Lateral Sclerosis Treatment Market Sales to Reach US$ 1021 Million in 2032 | CAGR of 5.6%
Investment in research and development by pharmaceutical companies is expected to propel the growth of the ALS market as they work to develop new...- Published at
- by prnewswire.com
mixedmixedNotice of Annual general meeting in Swedish Orphan Biovitrum AB (publ)
/PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the...- Published at
- by globenewswire.com
mixedmixedCORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics
New name, Greek for “zebra,” is the internationally-recognized symbol for the rare disease community Branding reflects Company’s commitment to...- Published at
- by marketscreener.com
mixedmixedLadRx Corporation Announces OTCQB Ticker Change to LADX
LadRx Corporation , a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX... | October 5, 2022- Published at
- by marketscreener.com
neutralneutralAdjusted financial outlook for 2022
Orphazyme A/SCompany announcement No. 35/2022 www.orphazyme.comCompany Registration... | September 25, 2022- Published at
- by marketscreener.com
mixedmixedCytRx Corporation Relaunches as LadRx Corporation
The New LadRx Corporation Name Will Be Effective on September 26, 2022 and Will Continue to Trade Under the Ticker CYTR until the new symbol has been approved by FINRA ... | September 23, 2022- Published at
- by marketscreener.com
mixedmixedOxford Biomedica : Appoints Catherine Moukheibir as Non-Executive Director
Oxford, UK - [14] December 2021: Oxford Biomedica plc , a leading gene and cell therapy group, announces the appointment of Ms Catherine Moukheibir to the Board as an Independent Non-Executive... | December 14, 2021